Provider Quick Links
Over 60% of Ovarian Cancers are not detected until late stage1 – we must change this, together
Aspira is changing the standard of care for patients and providers
Aspira Women’s Health is the first and only company that is offering a multi-modal comprehensive approach to Gynecologic Cancer Risk Assessment. With over 10 years of experience in Ovarian Cancer and Pelvic Mass risk detection our OVA1plus product provides an Ovarian Cancer risk assessment for women with Pelvic Masses. Aspira GenetiX assesses risk for hereditary gynecologic cancer risk. Detecting Ovarian Cancer early is the best way to make a difference and Aspira is working to do just that with our current test offerings and our future product pipeline.
Explore Our Products
-
Relentless pursuit of products to improve ovarian cancer detection and care. Learn about why OVA1plus is the best way to assess risk prior to surgery.
Learn More -
Hereditary breast and ovarian cancer detection and carrier screening. Learn about your inherited risk through genetic testing.
Learn More -
Aspira Synergy is a technology transfer platform that enables our customers to bring in-house the ability to perform specialty testing. Learn more about how to bring both OVA1plus and state-of-the-art genetic testing into your laboratory.
Learn More
Medical Societies
- National Cancer Institute, “SEER Stat Fact Sheets: Ovary Cancer,” http://seer.cancer.gov/statfacts/html/ovary.html.